Literature DB >> 4042523

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

K Nakamura, F Goto, W A Ray, C B McAllister, E Jacqz, G R Wilkinson, R A Branch.   

Abstract

Interethnic differences in debrisoquin and mephenytoin hydroxylation have been compared between normal white (n = 183) and Japanese (n = 100) subjects with the 8-hour urinary metabolic ratio of debrisoquin and the urinary S/R enantiomeric ratio of mephenytoin to identify extensive (EM) and poor (PM) metabolizers. In white subjects the frequency of PMs was 8.7% and 2.7% for debrisoquin and mephenytoin, respectively. In contrast, in Japanese subjects no PMs of debrisoquin were identified, while the incidence of PMs of mephenytoin was 18%. These substantial differences (P less than 0.001) in polymorphic distributions of oxidative drug metabolizing ability have implications for interethnic efficacy and toxicity of drugs and other xenobiotics that are metabolized by the involved cytochrome P-450 isozymes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4042523     DOI: 10.1038/clpt.1985.194

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  96 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Genetic polymorphism of CYP2D6 in a keralite (South India) population.

Authors:  B K Abraham; C Adithan; C H Shashindran; S Vasu; N A Alekutty
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

Review 3.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

4.  Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects.

Authors:  Myo-Kyoung Kim; Joo-Youn Cho; Hyeong-Seok Lim; Kyoung-Seop Hong; Jae-Yong Chung; Kyun-Seop Bae; Dal-Seok Oh; Sang-Goo Shin; Sang-Hun Lee; Dong-Ho Lee; Bumchan Min; In-Jin Jang
Journal:  Eur J Clin Pharmacol       Date:  2003-05-01       Impact factor: 2.953

Review 5.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.

Authors:  Masato Taguchi; Takashi Nozawa; Tomoki Kameyama; Hiroshi Inoue; Chihiro Takesono; Akiko Mizukami; Yukiya Hashimoto
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

7.  Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population.

Authors:  B S Doshi; R D Kulkarni; B L Chauhan; G R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

8.  Uses and misuses of definitions of genetic polymorphism. A perspective from population pharmacogenetics.

Authors:  T D Arias; L F Jorge; R Barrantes
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

9.  CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking.

Authors:  Margareta Ramsjö; Eleni Aklillu; Lilleba Bohman; Magnus Ingelman-Sundberg; Hyung-Keun Roh; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2010-05-25       Impact factor: 2.953

10.  Sparteine oxidation polymorphism in Greenlanders living in Denmark.

Authors:  K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.